Blood-Based Microrna Biomarker Signature of Early-Stage Pancreatic Ductal Adenocarcinoma with Lead-Time Trajectory in Pre-Diagnostic Samples
Warapen Treekitkarnmongkol,Jianliang Dai,Suyu Liu,Deivendran Sankaran,Tristian Nguyen,Seetharaman Balasenthil,Mark W. Hurd,Meng Chen,Hiroshi Katayama,Sinchita Roy-Chowdhuri,George A. Calin,Randall E. Brand,Paul D. Lampe,Tony Y. Hu,Anirban Maitra,Eugene J. Koay,Ann M. Killary,Subrata Sen
DOI: https://doi.org/10.1016/j.gastha.2024.08.002
2024-01-01
Gastro Hep Advances
Abstract:Background and Aims Clinically validated biomarker of pancreatic ductal adenocarcinoma (PDAC), CA19-9, has limited sensitivity and specificity for early-stage disease. Circulating miRNAs in plasma associated with cancer relevant pathways were developed as early detection biomarkers. Methods 2,083 miRNAs in 15 μl of plasma from multicenter age-matched cohorts (N=203: healthy controls, n=46; pancreatitis controls, n=36; diagnosed cases: n=121) and a pre-diagnostic PLCO age- and gender-matched cohort (N=96; controls, n=48; pre-diagnosed cases, n=48) were interrogated. A three-miRNA biomarker signature was developed for early-stage PDAC. Results The three-miRNA signature (let-7i-5p, miR-130a-3p and miR-221-3p) detected PDAC from healthy controls independently (AUC of stage I, II, I-IV = 0.970, 0.975, 0.974) and in combination with CA19-9 (AUC of stage I, II, I-IV = 1.000, 0.992, 0.995). It also discriminated chronic pancreatitis (AUC of stage I, II, I-IV = 0.932, 0.931, 0.929), improving performance of CA19-9 alone (AUC of stage I, II, I-IV = 0.763, 0.701, 0.735) in combination (AUC of stage I, II, I-IV = 0.971, 0.943, 0.951). Blinded validation in pre-diagnostic PLCO cohort revealed lead-time trajectory increase in AUC from 0.702 to 0.729 to 0.757 at twelve-, six-, and three-months before PDAC diagnosis, respectively. The signature also helped stratification of patients with different ctDNA and imaging subtypes. Conclusions Plasma miRNAs associated with oncogenic pathways may serve as PDAC early detection biomarkers.